What smart money is saying about Vetoquinol SA
2 funds in our archive have pitched Vetoquinol SA — most recently Ennismore European Smaller Companies Fund in December 2025.
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Fund coverage · 2 theses
- Ennismore European Smaller Companies FundDecember 2025
Vetoquinol is a resilient animal health company with high barriers to entry, improving mix, and structural growth supporting attractive upside.
Read the full thesis - Ennismore European Smaller Companies FundJune 2025
Vetoquinol is a fundamentally sound French animal health company with strong growth potential and a current market undervaluation, presenting an attractive investment opportunity.
Read the full thesis
Read every full thesis on Vetoquinol SA
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→